EU Regulator Advises Extra Birth Control Precautions for Patients of Lilly's Mounjaro

What happened

The European Medicines Agency’s medicines committee advised women taking birth-control pills and Eli Lilly’s Mounjaro to use backup contraception for four weeks after starting treatment and after each dose increase, or switch to non-oral contraception. The advice is to be disseminated by Lilly after a European Commission decision.

Confirmed

Global impact / market context

If patients add contraception or switch methods, Mounjaro use could involve extra steps and costs, potentially affecting treatment choices or persistence. The committee said evidence on interactions with oral contraceptives is limited, so the advice addresses uncertainty rather than confirming that the pills become less effective.

Analyst inference

The report identifies a regulatory recommendation, not a confirmed change in Lilly’s sales, costs, or product safety findings. Its commercial effect would depend on the European Commission’s decision, how widely clinicians communicate the advice, and whether patients change contraception or Mounjaro use.

Analyst inference

What to watch

1. Watch for the European Commission’s decision, which determines whether the committee’s recommendation proceeds to the next step described in the article. Confirmed
2. If the Commission decides in favor of the advice, Lilly is expected to share it with healthcare professionals, potentially shaping counselling for Mounjaro patients using pills. Confirmed
3. Patient or clinician responses could affect whether some users choose another contraceptive method or continue treatment, but the article provides no evidence of such changes. Analyst inference

Evidence

• Original source link unavailable